Seattle genetics achieves payment under antibody-drug conjugate collaboration with glaxosmithkline

Seattle genetics achieves milestone payment under antibody-drug conjugate collaboration with glaxosmithkline triggered by blenrep (belantamab mafodotin-blmf) fda approval.seattle genetics - approval of adc utilizing co's proprietary technology generates $20 million milestone payment,future royalties on worldwide net sales.
SGEN Ratings Summary
SGEN Quant Ranking